A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Trial Profile

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs ONCOS 102 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Acronyms MESOS
  • Sponsors Targovax
  • Most Recent Events

    • 07 Feb 2018 Results presented in a Targovax media release.
    • 07 Feb 2018 According to a Targovax media release, the company announced completion of the safety lead-in cohort and preliminary immune activation data. DSMB has reviewed all six patients, no concerns were raised and the DSMB have recommended that the randomized part of the trial can be initiated, with recruitment of another 24 patients.
    • 11 Dec 2017 According to a Targovax media release, the company expects to release immune response data in a subset of patients in February 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top